| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
1.85(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
136,870 |
194,989 |
260,525 |
524,601 |
| Total Sell Value |
$2,679,704 |
$3,814,194 |
$5,546,549 |
$13,449,119 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
19 |
38 |
75 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sato Vicki L |
Director |
– • – |
2024-04-15 |
4 |
AS |
$18.29 |
$30,471 |
D/D |
(1,666) |
118,043 |
|
-14% |
|
| Krognes Steve E. |
Director |
– • – |
2024-04-01 |
4 |
AS |
$20.50 |
$1,896,250 |
D/D |
(92,500) |
47,341 |
|
-25% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2024-03-29 |
4 |
GD |
$0.00 |
$0 |
I/I |
40,000 |
2,202,604 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2024-03-15 |
4 |
AS |
$20.10 |
$33,487 |
D/D |
(1,666) |
119,709 |
|
-23% |
|
| Sato Vicki L |
Director |
– • – |
2024-02-15 |
4 |
AS |
$18.37 |
$30,604 |
D/D |
(1,666) |
121,375 |
|
-16% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2024-02-14 |
4 |
AS |
$17.79 |
$24,995 |
D/D |
(1,405) |
143,605 |
|
-14% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2024-02-14 |
4 |
AS |
$17.66 |
$355,460 |
D/D |
(20,128) |
187,341 |
|
-14% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2024-02-13 |
4 |
S |
$17.29 |
$165,794 |
D/D |
(9,589) |
238,067 |
|
12% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2024-02-13 |
4 |
AS |
$17.29 |
$48,135 |
D/D |
(2,784) |
145,010 |
|
-10% |
|
| Krognes Steve E. |
Director |
– • – |
2024-02-13 |
4 |
S |
$17.29 |
$47,548 |
D/D |
(2,750) |
139,841 |
|
12% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2024-02-13 |
4 |
AS |
$17.29 |
$46,960 |
D/D |
(2,716) |
207,469 |
|
-10% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2024-02-08 |
4 |
OE |
$0.68 |
$34,000 |
D/D |
50,000 |
210,185 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2024-01-16 |
4 |
AS |
$18.42 |
$30,688 |
D/D |
(1,666) |
123,041 |
|
-16% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2024-01-10 |
4 |
AS |
$19.02 |
$88,785 |
D/D |
(4,668) |
147,794 |
|
-18% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2024-01-09 |
4 |
S |
$19.78 |
$154,640 |
I/I |
(7,818) |
2,268,363 |
|
24% |
|
| Krognes Steve E. |
Director |
– • – |
2024-01-05 |
4 |
S |
$19.43 |
$62,331 |
D/D |
(3,208) |
142,591 |
|
23% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2024-01-05 |
4 |
S |
$19.43 |
$193,756 |
I/I |
(9,972) |
198,777 |
|
23% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2024-01-05 |
4 |
S |
$19.43 |
$193,756 |
I/I |
(9,972) |
539,307 |
|
23% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2024-01-05 |
4 |
S |
$19.43 |
$339,695 |
I/I |
(17,483) |
2,276,181 |
|
23% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
89,520 |
272,957 |
|
- |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
53,720 |
170,157 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
53,720 |
162,434 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2023-12-15 |
4 |
AS |
$23.39 |
$38,968 |
D/D |
(1,666) |
124,707 |
|
-33% |
|
| Sato Vicki L |
Director |
– • – |
2023-11-15 |
4 |
AS |
$19.13 |
$31,871 |
D/D |
(1,666) |
126,373 |
|
12% |
|
| Sato Vicki L |
Director |
– • – |
2023-10-16 |
4 |
AS |
$20.66 |
$34,420 |
D/D |
(1,666) |
128,039 |
|
-19% |
|
416 Records found
|
|
Page 1 of 17 |
|
|
0.47 (3.14%) 
